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Abstract
Background—The handling and reporting of testicular tumours is difficult due to their rarity.
Design—A survey developed by the European Network of Uro-Pathology (ENUP) and sent to its 
members and experts to assess the evaluation of testicular germ cell tumours
Results—25 experts (E) and 225 ENUP members replied. Areas of disagreement included 
immaturity in teratomas, reported by 32% (E) but 68% (ENUP). Although the presence of rete 
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testis invasion was widely reported, the distinction between pagetoid and stromal invasion was 
made by 96% (E) but only 63% (ENUP). Immunohistochemistry was used in more than 50% of 
cases by 68% (ENUP) and 12% (E). Staging revealed the greatest areas of disagreement. Invasion 
of the tunica vaginalis without vascular invasion was interpreted as T1 by 52% (E) and 67% 
(ENUP), but T2 by the remainder. Tumour invading the hilar adipose tissue adjacent to the 
epididymis without vascular invasion was interpreted as T1: 40% (E), 43% (ENUP), T2: 36% (E), 
30% (ENUP) and T3: 24% (E), 27% (ENUP).
Conclusions—There is remarkable consensus in many areas of testicular pathology. Significant 
areas of disagreement included staging and reporting of histologic types, both of which have the 
potential to impact on therapy.
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Introduction
Testicular pathology creates many challenges for both expert and general 
histopathologists1, 2. Orchidectomies are relatively simple surgical procedures and therefore 
often performed by general or junior urologists in local hospitals where there is a lack of 
specialist genitourinary (GU) pathologists. For practicing pathologists, orchidectomy 
specimens pose two main problems. Firstly, these tumours are generally rare and only a 
handful may be encountered in a year, thus limiting the experience of the pathologist. The 
second problem is the huge range of testicular pathology. Within merely the germ cell 
tumours, the most commonly encountered testicular tumours, there is a protean range of 
morphology with many mimics and confounding patterns. This problem is magnified by the 
vast range of non-germ cell malignancies in the testicular parenchyma and spermatic cord. 
Some testicular tumour subtypes may be encountered only once in a career, if at all. Some 
are associated with rare clinical syndromes.
The handling and staging of testicular tumours, particularly germ cell tumours, may also be 
problematic. Both staging and typing may be affected by macroscopic examination. 
Although most germ cell tumours are now treated by surveillance3, the decision to give 
adjuvant therapy may be dependent on a number of clinic-pathological factors4. These 
include tumour stage, but there are a number of other predictive factors that have been 
suggested over the past 10 years not included in the current TNM terminology.
In some countries testicular pathology has been centralised, so that within the GU 
community there are certain designated experts who see a large volume of testicular tumours 
and therefore are more able to recognise the rarer variants. It has been shown that this 
subspecialisation may affect both typing and staging of tumours5, 6. There are numerous 
prospective and retrospective studies where pathology interpretation may be variable and 
greatly affect the results. There is a necessity of uniform pathology, not only to address the 
problems of correct diagnosis and treatment but also to address the consequences of 
pathology variability in clinical trials and avoid contamination of the literature with 
inaccurate prognostic factors. We therefore wished to examine the variability and conformity 
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in practice among both experts and general GU pathologists. This would hopefully highlight 
areas of agreement, and also areas where practice is variable and consensus needed.
Materials and Methods
A survey was developed by the steering group of the European Network of Uro-Pathology 
(ENUP). This focused on macroscopy, microscopy and especially known controversies in 
staging. The survey was sent to all 661 ENUP members as well as selected international 
experts. Experts were invited because of their known publication record or volume of their 
testicular pathology practice. The expert survey was analysed separately from the ENUP 
survey. The survey questions are listed in Table 1.
Results
Replies were received from 25 experts (E) and 225 ENUP members. Both groups had 
remarkably similar responses for many questions.
Demographics
The experts worked in 10 different countries: 13 in North America, 11 in Europe and one in 
New Zealand. ENUP members came from 22 European countries, the largest representation 
coming from the UK with 17% (38), Spain 14% (31), Italy 9% (21) and Germany 7% (16). 
This may at least partly reflect that most surveys are conducted in English.
Of the experts, 24 received more than 20 testis cases in consult or routine practice per year 
and 6 (24%) received more than 100 cases. 48% of the experts had more than half their cases 
as consults. Among ENUP members, 39% (87) saw fewer than 20 and 50% (113) saw 
between 20 and 50. 2% (4) of ENUP members saw more than half their cases as consults. 
For clarity, only percentages of each cohort will be reported for the remaining results.
Macroscopy
A summary of the results are displayed in Table 2. Notable differences of opinion in 
technique were noted. Ink was not used by 62% (ENUP) and 52% (E). Of those using ink, 
experts all used one colour. While 93% of ENUP members did the same, 6% used two 
colours and one member used 3 colours. Other significant differences were in methods of 
tumour measurement where some measured the tumour only in 1 dimension, while others 
used two or three measurements. Tumour blocks were taken by a variety of methods. A 
subjective method was used, correlating to tumour size, in 65% (ENUP) and 56% (E). The 
classical method of a fixed number of blocks per cm was used by 24% (ENUP) and 22% 
(E). Others used no fixed protocol and commented on their specific method. Some experts 
said they would take more blocks from a suspected seminoma than from a non-seminoma.
Classification and microscopy
A summary of the results is displayed in Table 3. Nearly all respondents from both groups 
classified by WHO 2004. Significant differences included recording of immaturity in 
teratoma which was reported by 68% (ENUP) but only 32% of experts. Respondents were 
asked whether they made any assessment of ‘differentiation’ in seminomas. Some authors 
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have previously reported mitotic rates or so called ‘anaplastic’ seminomas and we wished to 
investigate whether pathologists reported these features.7–9. This was done by 12% (ENUP) 
and 28% (E) though methods were very variable including mitotic counts, and nuclear 
morphology. Reporting the type of tumour involved in vascular invasion was reported by 
54% (ENUP) and 56% (E). Also, there were differences on whether blood vessel invasion 
should be distinguished from lymphatic invasion. This was reported by 41% (ENUP) and 
28% (E). Invasion of the rete testis was reported by 94% (ENUP) and 96% (E), though when 
asked whether any distinction was made between pagetoid and stromal invasion of the rete 
(Figures 1a and b), this was done by 63% (ENUP) and 96% (E).
TNM staging
The detailed usage of TNM classification is presented in Table 3 and the expert differences 
in Figure 2. Major differences included the staging of tumour invading the inner serosal 
lining of the testis but not the outer layer with no vascular invasion. This would be staged as 
T1 by 67% (ENUP) and 52% (E) and T2 by the remainder. Tumour invading the hilar fatty 
tissue adjacent to the epididymis with no vascular invasion would be staged T1 by 43% 
(ENUP) and 40% (E), T2 by 30% (ENUP) and 36% (E) and T3 by 27% (ENUP) and 24% 
(E). A tumour deposit in the upper cord with a separate tumour in the testis associated with 
vascular invasion would be staged as T2 with a soft tissue deposit by 23% (ENUP) and 28% 
(E) and T3 by 75% (ENUP) and 68% (E). The remainder made comments that they would 
stage as a metastasis.
Immunochemistry and genetics
Use of immunochemistry is presented in Table 4 and specific antibodies used presented in 
Figure 3. Isochromosome 12p assessment was requested on challenging cases by 7% 
(ENUP) and 48% (E).
Discusssion
This survey highlights a surprising degree of concordance between urological pathologists 
whether or not they have a specialist interest in testicular pathology. Although some 
protocols are evidence based, others appear to have evolved with very little evidence base, 
however logic has dictated certain approaches which are widely adopted. Pathologists are 
also guided by expert opinion and by cancer guidelines which have been published by 
national pathological associations10..
Macroscopic protocols are broadly similar. However opinion was split on the use of ink. 
While only one colour is used as a maximum by all the expert groups, two or more colours 
are used by some ENUP members. This routine appears to be unnecessary for total 
orchidectomy specimens. The use of ink is necessary on partial orchidectomy specimens 
where it is the only way that margin positivity can be demonstrated due to the lack of an 
anatomic boundary. The taking of a cord block before incising the testis was widespread. 
However some pathologists receive their testes already incised by the surgeon. The logic of 
this is to ensure formalin fixation, as suboptimal fixation can compromise tissue typing. The 
taking of the cord block prior to excision derives from a sole paper and serves to avoid 
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contamination of the margin, and a false positive report of vascular invasion11. It should be 
noted, however, that it is not possible to protect testicular parenchyma from contamination of 
vessels by free floating tumour cells in a similar way.
A majority of pathologists take tumour blocks in a subjective manner, but claim that the 
number of blocks correlates with tumour size. It was commented by some experts that they 
sample probable seminomas more widely to look for non-seminomatous transformation. 
Tumour size is most commonly measured in three diameters, but by a minority in two 
dimensions. The maximal tumour dimension has been shown in many studies to be 
prognostically significant, particularly in seminoma. One pooled analysis of data from 4 
cohort studies of 638 patients showed that if tumours were greater than 4cm in maximum 
diameter there was a two-fold risk of recurrence and the importance of tumour size is 
strongly supported by more recent studies. 4, 12–14. It would appear logical that it is 
important to give as a minimum the maximal diameter. Blocking of the rete testis, normal 
parenchyma and examination of the tunics appears now to be very widely accepted. Rete 
testis invasion has been shown in some studies to be an important prognostic factor4, 15, 
though this may be a surrogate for tumour size and has been disputed by other studies16 
Including recent large series which did not however include pathological review 12.
While nearly all respondents report on rete testis invasion, 37% of ENUP members did not 
distinguish between pagetoid invasion, which is probably a phenomenon related to spread of 
intratubular germ cell neoplasia into the rete, and true interstitial invasion. This shows the 
possible dangers of relying on extraction of pooled pathological data from multiple centres 
without central review, which is often done in clinical studies.
Reporting vascular invasion was virtually universal in the survey and has an excellent 
evidence base, particularly for non seminomas17–22. The evidence that vascular invasion is 
an important prognostic factor in seminoma is much however less certain 4, 12, 23 . There 
were general disagreements in whether lymphatics should be reliably distinguished from 
small venules. One trial has suggested that this is an important distinction24, but older and 
more recent work suggests that such distinctions are not possible on H and E25, 26. There 
was also disagreement on whether the type of tumour present within vessels should be 
reported. The is no evidence to support this. In pure seminomas this should be self apparent, 
and the vast majority of non seminoma cases show vascular invasion by the embryonal 
carcinoma component.
Classification by the WHO 2004 now appears widespread. The British Testicular Panel 
(BTTP) devised a classification in the 1960s27 and is still used by a few UK based 
pathologists though is not recommended in the latest Royal College of Pathologists 
dataset10.
77% of ENUP and 92% of the experts reported the percentages of all elements of a germ cell 
tumour. There is considerable work supporting that the percentage of embryonal carcinoma 
is prognostically significant. A surveillance study of 373 men with stage 1 non 
seminomatous germ cell tumours showed that the percentage of embryonal carcinoma 
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predicted relapse28. This has been supported by numerous other smaller studies18, 29, 30. 
More recent cohort studies, one on 1,226 patients22, have supported this.
The degree of immaturity in a teratoma has been shown to have little impact on disease 
natural history. Interestingly 68% of ENUP still reported on this while only 32% of experts 
would do so: an example of a practice where less is done by the experts because of insight 
that it has little prognostic importance.
The most important differences were in tumour staging by TNM, and here there was a lack 
of consistency despite over 95% of respondents using it. This is reflected in a very poor 
evidence base, where apart from vascular invasion in non-seminomas, the TNM staging 
appears to be largely unhelpful. Tunica vaginalis invasion is staged as T2 in the current 
TNM classification, though in fact there is no evidence for this in the literature, despite 
being an anatomical boundary. The experts and ENUP members were broadly split on how 
to interpret tumour involvement of the inner serosal lining part of the tunica vaginalis. 
Although anatomically both serosal linings represent the tunica vaginalis, there is a 
reluctance of pathologists to upstage to T2 in these circumstances, possibly because some 
believe that the inner serosal lining represents the tunica albiginea.
There was even further disagreement on the staging of hilar fat involvement, without 
vascular invasion: split fairly evenly between T1, T2 and T3. Recent papers have suggested 
that this is a poor prognostic factor, but many are reluctant to stage as T331.
The variation seen in this survey suggests a number of consequences. Firstly, the variation in 
reporting TNM stage and rete testis invasion will affect any analysis of prognostic factors in 
germ cell tumours especially in pooled data. Any reliance on extracting the data from 
pathology reports should be treated with extreme caution as it may be unreliable.
Immunochemistry was used in far fewer cases among the expert group, reflecting the 
familiarity of those pathologists with these tumours. However there were significant 
differences in the markers that were utilised between both groups (Figure 3). Notably, 
OCT3/432 was used far more among experts than amongst ENUP members. It has been 
shown to be both sensitive and specific for embryonal carcinoma and seminoma, and widely 
promulgated in many articles2, 33. A recent expert opinion paper from ISUP may promote 
changes in some practices34. The lack of its use in many departments may reflect budget 
restraints or caution in developing new tests. The same holds true for SALL-435, 36 and 
Glipican-337, 38.
Finally, molecular testing for isochromosome 12p may be helpful in rare and challenging 
cases, for instance to distinguish dermoid cysts from mature teratomas.39. It was used by 
half the expert group, it only 7% of the ENUP group, again probably reflecting a lack of 
local availability and molecular expertise.
In conclusion we have shown that while some areas of testicular pathology show remarkable 
degrees of consensus, others show great variability which may lead to differences in the 
power of prognostic information provided and even effect treatment decisions. International 
agreement and consensus statements may lessen the variability in these areas.
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Figure 1. 
Figure 1a. Rete testis showing pagetoid invasion by intra tubular germ cell neoplasia, 
unclassified
Figure 1b. Rete testis, showing widespread invasion of the interstitium by seminoma.
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Figure 2. 
Variation in tumour-node-metastasis (TNM) staging in particular scenarios by the expert 
panel.
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Figure 3. 
Frequency of use of different immunochemical antibodies by ENUP members and experts. 
E=Experts ENUP=European network of Uro-Pathology.
Berney et al. Page 12
Histopathology. Author manuscript; available in PMC 2016 September 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Berney et al. Page 13
Table 1
Testis Questionnaire.
1 Please state your name
2 In which country do you practice?
3 Approximately how many radical orchidectomy specimens or consultation testis cases do you receive per year?
1–20
20–50
50–100
Greater than 100
4 Of these, what percentage is in consultation for second opinon/referred from a nonspecialist centre?
0%
0–25%
25%–50%
Greater than 50%
5 How do you receive the specimen?
Fresh
Formalin fixed
Bouin’s fixed
6 Do you perform frozen section diagnosis of testicular tumours?
Yes, for all cases
For selected cases only when
considering partial
orchidectomy
Never
7 Do you ever take fresh tissue for biobanking?
Y/N
8 If you receive fixed specimens do the surgeons incise them before receipt?
Yes
No
Sometimes
9 Do you routinely take the cord margin?
Y/N
10 How many other cord blocks do you routinely take?
None
1
2 or more
Only if there is a macroscopic
abnormality
11 Do you routinely take cord blocks before incising the testis?
Y/N
12 Do you use any ink on any part of the specimen?
Y/N
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13 If yes, how many colours?
1
2
3
14 What methods do you use to decide number of tumour blocks?
Fixed number regardless of size
Subjective decision, correlating o size
Fixed number of blocks per cm
tumour diameter
No set protocol
Other method
15 Do you measure the cord length?
Y/N
16 Do you measure the testis size (including the tumour)?
Y/N
17 Do you measure the tumour size?
Y/N
18 If yes, how do you measure the tumour?
Ruler, maximum diameter on cut section
Ruler, 2 diameters on cut section
Ruler, 3 diameters
Estimation, maximum diameter on cut section
Estimation, 2 diameters on cut section
Estimation, 3 diameters
Comparisons to objects such as golf balls, bird eggs, nuts (specify)
Subjective description
19 Do you routinely take a block(s) to examine the rete testis and hilum to examine its involvement by tumour?
Y/N
20 Do you comment on the outer layer of the tunica vaginalis and whether it is stuck down to the testis or not?
Y/N
21 Do you always take a block of grossly normal testicular parenchyma if present?
Y/N
22 Any other comments on special macro techniques?
23 What system do you use to classify GCTs?
WHO 2004
British Testicular Tumour Panel
Classification
Earlier WHO
Both BTTP and WHO
24 Do you always report the percentages of different tumour types of a germ cell tumor?
Yes
No
Only percentage of embryonal carcinoma
Other
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25 For teratoma do you report the degree of immaturity?
Y/N
26 Do you report the presence of primitive neuroectodermal elements?
Y/N
27 Do you always report whether vascular invasion is present or absent?
Y/N
28 Do you report the type of tumour involved in vascular invasion?
Y/N
29 Do you distinguish between lymphatic and blood vessel invasion?
Y/N
30 If you see blood vessel invasion but no stromal invasion in the cord (distant from the tumour) do you stage as 
T2 or T3?
T2
T3
31 Do you always report rete testis invasion?
Y/N
32 Do you distinguish between pagetoid invasion of the rete epithelium and invasion of the rete stroma?
Y/N
33 For seminoma, do you make any assessment of ‘differentiation’?
Y/N
(Please comment on method)
34 Do you routinely report the presence of IGCNU?
Y/N
35 Do you always use the TNM staging classification?
Y/N
36 How would you stage the following scenario: Tumour invading the tunica albiginea and the inner serosal lining 
of the testis but not the outer layer, no vascular invasion?
T1
T2
T3
37 How would you stage the following scenario: Tumour invading the epididymis, no vascular invasion?
T1
T2
T3
38 How would you stage the following scenario: Tumour invading the hilar fatty tissue adjacent to the epididymis, 
no vascular invasion?
T1
T2
T3
39 How would you stage the following scenario: Tumour deposit in the upper cord with separate tumour confined 
to testis, vascular invasion present?
T2
T3
40 How often do you use immunochemistry in the diagnosis of testicular tumours?
Every case
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50–100% of cases
10–50% of cases
Less than 10% of cases
Never
41 Which immunochemical antibodies do you use in your routine diagnosis of germ cell malignancies? Please 
tick if used
PLAP
Podoplanin
CD117
Alpha feto-protein
Beta hCG
OCT3/4
CD30
NANOG
SALL-4
Glipican-3
Cytokeratin-7
Cytokeratin AE1/3
EMA
SOX-2
SOX-17
42 Do you ever ask for i12p assessment on challenging cases?
Y/N
43 If you have any further comments on important controversies in testicular pathology then please outline them 
below.
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Table 4
Frequency of use of Immunochemistry for testicular tumours.
Use of immunochemistry in the testis ENUP N (%) Experts N (%)
Every case 78 (35%) 0 (0%)
50–100% of cases 75 (33%) 3 (12%)
10–50% of cases 54 (24%) 9 (36%)
Less than 10% of cases 17 (8%) 13 (52%)
Never 0 (0%) 0 (0%)
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